Ontario Industry Updates Guest User Ontario Industry Updates Guest User

Nanovista Receives $1.8M Investment to Develop Advanced Imaging Agents

Nanovista Inc., a start-up company co-founded by Drs. David Jaffray, Jinzi Zheng, and Christine Allen of UHN and the University of Toronto, recently received investments of $1.8M with the help of GreenSky Capital Inc. and its affiliated venture capital funds.

Nanovista also recently welcomed Steven Chackowicz as its new CEO. A serial entrepreneur, he has experience in leadership roles in companies that include Exact Imaging, Aspect Imaging and VisualSonics. 

Read More
Showcasing Ontario's High Potential Companies: Niagara Emerging Health Sciences Company Forum - Part 2
OBIO News Guest User OBIO News Guest User

Showcasing Ontario's High Potential Companies: Niagara Emerging Health Sciences Company Forum - Part 2

This week, in Part 2 of a blog that began last week, we review the Niagara Emerging Health Science Company Forum, held in Niagara-on-the-Lake on Feb 1-2, 2018.

The forum brought together CEOs and senior executives from high potential Canadian health science companies with senior leadership from American investors and strategics in beautiful Niagara-on-the-Lake for two days of panel presentations, executive roundtables, and networking dinners.

Read More
OBIO News Guest User OBIO News Guest User

OBIO Niagara Forum featured in VC Michael Greeley's Blog

Michael Greeley, Co-Founder and General Partner at Flare Capital Partners, an early stage healthcare technology venture firm, and a Founding General Partner Flybridge Capital Partners blogged about Ontario's Health Tech Scene. Michael was a panelist at OBIO's recent Niagara on the Lake Health Sciences Emerging Company Forum, and wrote about his overall impression of the Ontario's emerging health tech companies.

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

OBIO CAAP Company: ImmunoBiochem Corporation Enters Into Collaboration & Option Agreement with Advanced Proteome Therapeutics

Advanced Proteome Therapeutics Corporation (APC), a therapeutics discovery and development company, and ImmunoBiochem Corporation, today announced entering into a Collaboration and Option agreement to develop superior antibody-drug conjugates. The companies will evaluate the prospect of combining ImmunoBiochem’s proprietary antibody and APC’s site-selective conjugation technology to produce ADCs with superior properties, targeting triple-negative breast cancer.

Read More
Ontario Industry Updates Guest User Ontario Industry Updates Guest User

OBIO CAAP Company: Biotagenics Partners with University of Ottawa and CHEO on $9.1 Million Project with Genome Canada to Develop Therapies for Inflammatory Bowel Disease

Toronto – Biotagenics Inc., a microbiome-based platform company developing novel therapeutics and diagnostics is the industrial collaborator on a $9.1 million CAD ($7.4 million USD) project led by academic collaborators at University of Ottawa and Children’s Hospital of Eastern Ontario (CHEO) to study the clinical application of microbiome-based precision medicine in pediatric inflammatory bowel disease (IBD).

Read More